<p>Xenon Pharmaceuticals（纳斯达克代码：XENE - 获取免费报告）于周四发布了其财报。该生物制药公司报告本季度每股收益为（$1.31），低于市场共识预期的（$1.20），差距为（$0.11），据 Zacks 报道。在去年同期，该公司每股收益为（$0.84）。</p>
<p>获取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
<h2>Xenon Pharmaceuticals 价格表现</h2>
<ul>
<li>布里斯托尔 - 迈尔斯斯奎布的重大收购：在两笔生物技术交易中投资 181 亿美元</li>
</ul>
<p>周四，XENE 股票上涨 0.34 美元，达到 44.92 美元。该股票交易量为 709,123 股，而其平均交易量为 917,995 股。该股票市值为 34.7 亿美元，市盈率为-11.55，贝塔值为 0.96。Xenon Pharmaceuticals 的股价在过去一年内最低为 26.74 美元，最高为 46.60 美元。该股票的 50 日移动平均价格为 42.51 美元，200 日移动平均价格为 40.94 美元。</p>
<h2>分析师评级上调与下调</h2>
<p>多位股票分析师对 XENE 股票发表了评论。Chardan Capital 在 11 月 19 日的研究报告中将 Xenon Pharmaceuticals 的股票评级上调至 “强力买入”。摩根大通在 1 月 9 日的报告中将 Xenon Pharmaceuticals 的目标价格从 60.00 美元上调至 62.00 美元，并给予该股票 “超配” 评级。富国银行在 12 月 11 日的报告中将 Xenon Pharmaceuticals 的目标价格从 44.00 美元上调至 48.00 美元，并给予该公司 “超配” 评级。Needham &amp; Company LLC 在 11 月 4 日的研究报告中重申了 “买入” 评级，并对 Xenon Pharmaceuticals 的股票设定了 55.00 美元的目标价格。最后，Stifel Nicolaus 在 2 月 10 日的报告中对 Xenon Pharmaceuticals 设定了 66.00 美元的目标价格。两位研究分析师给予该股票 “强力买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Xenon Pharmaceuticals 目前的平均评级为 “买入”，共识目标价格为 55.17 美元。</p>
<p><strong>获取我们对 Xenon Pharmaceuticals 的最新股票分析</strong></p>
<h2>Xenon Pharmaceuticals 的内部交易</h2>
<p>在其他 Xenon Pharmaceuticals 的新闻中，首席执行官 Ian Mortimer 在 1 月 2 日的交易中出售了 40,000 股公司股票。该股票以平均价格 44.43 美元出售，总交易额为 1,777,200.00 美元。出售完成后，首席执行官直接持有公司 6,000 股股票，价值约 266,580 美元。此次交易使其持股减少了 86.96%。该出售在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。内部人士在上个季度共出售了 65,302 股公司股票，价值 2,924,128 美元。公司内部人士持有 4.07% 的股票。</p>
<h2>机构投资者对 Xenon Pharmaceuticals 的看法</h2>
<p>机构投资者最近调整了对该公司的持股。Freestone Grove Partners LP 在第三季度收购了 Xenon Pharmaceuticals 的新股份，价值约 271,000 美元。Virtus Investment Advisers LLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 74.0%。Virtus Investment Advisers LLC 目前持有 6,037 股该生物制药公司的股票，价值 271,000 美元，此前在该期间内又购买了 2,568 股。Magnetar Financial LLC 在第四季度收购了 Xenon Pharmaceuticals 的新股份，价值约 231,000 美元。Cibc World Markets Corp 在第四季度收购了 Xenon Pharmaceuticals 的新股份，价值约 225,000 美元。最后，Mackenzie Financial Corp 在第四季度收购了 Xenon Pharmaceuticals 的新股份，价值 210,000 美元。机构投资者和对冲基金持有公司 95.45% 的股票。</p>
<h2>Xenon Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Xenon Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于发现和开发针对中枢和外周神经系统离子通道的新型小分子药物。该公司的研究重点集中在神经和疼痛疾病上，包括癫痫、偏头痛和神经性疼痛，通过调节关键的离子通道蛋白来恢复正常的神经功能。Xenon 的科学平台利用离子通道生物学和基于结构的药物设计的进展，识别和优化具有潜在改进的安全性和疗效特征的治疗候选药物。</p>
<p>该公司的产品管线包括多个临床前和临床项目。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Xenon Pharmaceuticals</li>
<li>预测 iPhone 的人说买入这三家公司</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>这让我感到愤怒</li>
<li>没有人谈论的免费股票推荐</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Xenon Pharmaceuticals 吗？</h2>
<p>在考虑 Xenon Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Xenon Pharmaceuticals 并不在名单上。</p>
<p>虽然 Xenon Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Xenon制药

<p>Xenon Pharmaceuticals（纳斯达克代码：XENE）报告的季度每股收益为（$1.31），低于分析师预期的（$1.20），差距为$0.11。与去年同期的每股收益（$0.84）相比有所下降。该股上涨$0.34，报$44.92，市值为$34.7 亿。分析师对该股的平均评级为 “买入”，一致目标价为$55.17。内部交易方面，首席执行官 Ian Mortimer 出售了 40,000 股。机构投资者持有该公司 95.45% 的股份</p>

<p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11), Zacks reports. During the same period last year, the company earned ($0.84) EPS.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals（纳斯达克代码：XENE - 获取免费报告）于周四发布了其财报。该生物制药公司报告本季度每股收益为（$1.31），低于市场共识预期的（$1.20），差距为（$0.11），据 Zacks 报道。在去年同期，该公司每股收益为（$0.84）。</p>
</div><p>Get <strong>Xenon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Xenon Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Xenon Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 价格表现</h2>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>布里斯托尔 - 迈尔斯斯奎布的重大收购：在两笔生物技术交易中投资 181 亿美元</li>
</ul>
</div><p>Shares of XENE stock traded up $0.34 on Thursday, reaching $44.92. 709,123 shares of the stock were exchanged, compared to its average volume of 917,995. The stock has a market cap of $3.47 billion, a PE ratio of -11.55 and a beta of 0.96. Xenon Pharmaceuticals has a one year low of $26.74 and a one year high of $46.60. The stock has a 50 day moving average price of $42.51 and a 200 day moving average price of $40.94.</p>
<div class="lb-trans"><p>周四，XENE 股票上涨 0.34 美元，达到 44.92 美元。该股票交易量为 709,123 股，而其平均交易量为 917,995 股。该股票市值为 34.7 亿美元，市盈率为-11.55，贝塔值为 0.96。Xenon Pharmaceuticals 的股价在过去一年内最低为 26.74 美元，最高为 46.60 美元。该股票的 50 日移动平均价格为 42.51 美元，200 日移动平均价格为 40.94 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of equities analysts have commented on XENE shares. Chardan Capital upgraded shares of Xenon Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 19th. JPMorgan Chase &amp; Co. boosted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an &#34;overweight&#34; rating in a report on Friday, January 9th. Wells Fargo &amp; Company raised their price target on Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, December 11th. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, November 4th. Finally, Stifel Nicolaus set a $66.00 target price on Xenon Pharmaceuticals in a report on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of &#34;Buy&#34; and a consensus price target of $55.17.</p>
<div class="lb-trans"><p>多位股票分析师对 XENE 股票发表了评论。Chardan Capital 在 11 月 19 日的研究报告中将 Xenon Pharmaceuticals 的股票评级上调至 “强力买入”。摩根大通在 1 月 9 日的报告中将 Xenon Pharmaceuticals 的目标价格从 60.00 美元上调至 62.00 美元，并给予该股票 “超配” 评级。富国银行在 12 月 11 日的报告中将 Xenon Pharmaceuticals 的目标价格从 44.00 美元上调至 48.00 美元，并给予该公司 “超配” 评级。Needham &amp; Company LLC 在 11 月 4 日的研究报告中重申了 “买入” 评级，并对 Xenon Pharmaceuticals 的股票设定了 55.00 美元的目标价格。最后，Stifel Nicolaus 在 2 月 10 日的报告中对 Xenon Pharmaceuticals 设定了 66.00 美元的目标价格。两位研究分析师给予该股票 “强力买入” 评级，十一位给予 “买入” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Xenon Pharmaceuticals 目前的平均评级为 “买入”，共识目标价格为 55.17 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Xenon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Xenon Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Insider Transactions at Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 的内部交易</h2>
</div><p>In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the completion of the sale, the chief executive officer directly owned 6,000 shares of the company's stock, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 65,302 shares of company stock valued at $2,924,128 in the last quarter. 4.07% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Xenon Pharmaceuticals 的新闻中，首席执行官 Ian Mortimer 在 1 月 2 日的交易中出售了 40,000 股公司股票。该股票以平均价格 44.43 美元出售，总交易额为 1,777,200.00 美元。出售完成后，首席执行官直接持有公司 6,000 股股票，价值约 266,580 美元。此次交易使其持股减少了 86.96%。该出售在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。内部人士在上个季度共出售了 65,302 股公司股票，价值 2,924,128 美元。公司内部人士持有 4.07% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Xenon Pharmaceuticals 的看法</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Freestone Grove Partners LP acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at approximately $271,000. Virtus Investment Advisers LLC grew its holdings in Xenon Pharmaceuticals by 74.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company's stock valued at $271,000 after purchasing an additional 2,568 shares during the period. Magnetar Financial LLC bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $231,000. Cibc World Markets Corp bought a new stake in Xenon Pharmaceuticals in the fourth quarter valued at approximately $225,000. Finally, Mackenzie Financial Corp acquired a new stake in Xenon Pharmaceuticals in the fourth quarter worth $210,000. Institutional investors and hedge funds own 95.45% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Freestone Grove Partners LP 在第三季度收购了 Xenon Pharmaceuticals 的新股份，价值约 271,000 美元。Virtus Investment Advisers LLC 在第四季度将其在 Xenon Pharmaceuticals 的持股增加了 74.0%。Virtus Investment Advisers LLC 目前持有 6,037 股该生物制药公司的股票，价值 271,000 美元，此前在该期间内又购买了 2,568 股。Magnetar Financial LLC 在第四季度收购了 Xenon Pharmaceuticals 的新股份，价值约 231,000 美元。Cibc World Markets Corp 在第四季度收购了 Xenon Pharmaceuticals 的新股份，价值约 225,000 美元。最后，Mackenzie Financial Corp 在第四季度收购了 Xenon Pharmaceuticals 的新股份，价值 210,000 美元。机构投资者和对冲基金持有公司 95.45% 的股票。</p>
</div><h2>Xenon Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Xenon Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.</p>
<div class="lb-trans"><p>Xenon Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于发现和开发针对中枢和外周神经系统离子通道的新型小分子药物。该公司的研究重点集中在神经和疼痛疾病上，包括癫痫、偏头痛和神经性疼痛，通过调节关键的离子通道蛋白来恢复正常的神经功能。Xenon 的科学平台利用离子通道生物学和基于结构的药物设计的进展，识别和优化具有潜在改进的安全性和疗效特征的治疗候选药物。</p>
</div><p>The company's pipeline comprises multiple preclinical and clinical programs.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个临床前和临床项目。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Xenon Pharmaceuticals</li>
<li>The Man Who Predicted the iPhone Says Buy These 3 Companies</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>This makes me furious</li>
<li>The free stock picks nobody’s talking about</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Xenon Pharmaceuticals</li>
<li>预测 iPhone 的人说买入这三家公司</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>这让我感到愤怒</li>
<li>没有人谈论的免费股票推荐</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=XENE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Xenon Pharmaceuticals 吗？</h2>
</div><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Xenon Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Xenon Pharmaceuticals 并不在名单上。</p>
</div><p>While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Xenon Pharmaceuticals 目前在分析师中获得了 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Xenon 制药（NASDAQ:XENE）公布季度财报，每股收益比预期低 0.11 美元